May 2026 Monthly Summary: Delivered a focused analytics script to summarize Compute Engine Spot/preemptible VM lifecycle logs in hartwigmedical/scripts, improving visibility into VM preemption events and lifecycle transitions. This supports faster incident analysis, capacity planning, and cost optimization through lifecycle analytics. The change is tracked as INFRA-2702: Add admin/gcp_preempt_stats and includes commit 9aafb29dcb095166d4349d321c15e49267aced98.

March 2026 monthly summary for hartwigmedical/actin focusing on features and bugs delivered, code quality, and business impact. 1) Key features delivered: - CUPPA-to-DOID mapping for tumor location evaluation, with a TSV-based mapping read into the system for configurability via the cuppa_doid_mapping_tsv CLI argument. - Rule behavior adjusted to issue a warning for conclusive CUPPA predictions (>80% likelihood) that match the queried DOID, instead of failing, improving robustness for cancer types with unknown primary origins. - Architectural improvement: Moved TumorOriginInterpreter from the report module into a shared common area and integrated it into PrimaryTumorLocationBelongsToDoid for broader reuse. 2) Major bugs fixed: - Implemented warning-based handling for conclusive CUPPA predictions to prevent unnecessary failures when primary origin data is incomplete or ambiguous, aligned with PR feedback and test updates. - Updated tests to cover the new behavior and mapping configuration. 3) Overall impact and accomplishments: - Increased reliability and resilience of tumor location evaluation in the face of incomplete or ambiguous CUPPA predictions, reducing false negatives/failures and enabling smoother downstream decision support. - Improved maintainability through code reuse (common TumorOriginInterpreter) and configurable mapping, enabling quicker future adjustments. 4) Technologies/skills demonstrated: - TSV-based mapping configuration, CLI-driven feature toggles, and rule-based decision logic. - Cross-module refactoring and reuse of a shared interpreter across components. - PR feedback processing, test-driven validation, and documentation of new behavior for stakeholders.

February 2026 monthly summary for hartwigmedical/actin focused on molecular pathology reports enhancements in the UI and data typing, plus test maintenance and stability improvements. Delivered a reorganized UI for molecular sections, introduced a CopyNumberType adapter for robust JSON mapping, and strengthened visual hierarchy. Addressed regression/test issues, updated references, and incorporated PR feedback to improve reliability and developer velocity.